Best Practices

Activating the Immune System to Treat Multiple Myeloma

Publish date: December 11, 2017
This article was funded and directed by Bristol-Myers Squibb.

 

Sagar Lonial, MD

Chief Medical Officer, Winship Cancer Institute of Emory University

Chair, Dept. of Hematology and Medical Oncology, Emory School of Medicine

Faculty/Faculty Disclosure

Dr. Lonial reports that he is a compensated consultant for Bristol-Myers Squibb; Celgene Corporation; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Millennium Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Onyx Pharmaceuticals, Inc.

Click here to read the supplement

Recommended Reading

Cyclophosphamide after transplant reduced GVHD in myeloma patients
MDedge Hematology and Oncology
Late-breaking abstracts highlight treatment advances in CLL, myeloma, and more
MDedge Hematology and Oncology
CAR T-cells gain ground against hematologic cancers
MDedge Hematology and Oncology
GSI may boost BCMA CAR T-cell therapy efficacy in myeloma
MDedge Hematology and Oncology
Anti-BCMA CAR T-cell therapy being fast tracked at FDA
MDedge Hematology and Oncology
FDA lifts partial hold on nivolumab trials
MDedge Hematology and Oncology
Enzyme may be target for MM treatment
MDedge Hematology and Oncology
Group develops MM-specific CAR T-cell therapy
MDedge Hematology and Oncology
Team identifies genetic differences between MM patients
MDedge Hematology and Oncology
PTSD can persist in cancer survivors
MDedge Hematology and Oncology